Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Thyroid Neoplasms 13Thyroid Carcinoma, Anaplastic 4Squamous Cell Carcinoma of Head and Neck 4Salivary Gland Neoplasms 4Carcinoma, Medullary 4Tongue Neoplasms 3Thyroid Diseases 3Thyroid Cancer, Papillary 3Head and Neck Neoplasms 2Adenocarcinoma, Follicular 2Wilms Tumor 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

Filgrastim 2tipifarnib 1oblimersen 1entrectinib 1entinostat 1Topotecan 1Thiotepa 1Temozolomide 1Sorafenib 1Ritonavir 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Irinotecan 1Indinavir 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Sorafenib × Head & Neck × Clear all
NCT01502410 2018-06-26

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 14 charts
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Wilms Tumor, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡